drugset / Trial / NCT03908008

Efficacy and Safety Study of MT10107 in the Treatment of Glabella Line

NCT03908008

Phase 3 Completed 136 enrolled Medy-Tox
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study design is a parallel, active drug controlled, double blind, randomized, multi-centered, phase III clinical trial to compare the efficacy and safety of MT10107 versus BOTOX® in treatment of glabella line.

Timeline

Start
2014-01
Primary completion
2014-05
Completion
2014-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic 20 iu Intramuscular
Subject CORETOX® Unknown 20 iu Intramuscular

Indications

No indication recorded.